WO2026021078 - USE OF PHARMACEUTICAL COMPOSITION IN TREATMENT OF MIGRAINE
National phase entry is expected:
Publication Number
WO/2026/021078
Publication Date
29.01.2026
International Application No.
PCT/CN2025/102456
International Filing Date
20.06.2025
Title **
[English]
USE OF PHARMACEUTICAL COMPOSITION IN TREATMENT OF MIGRAINE
[French]
UTILISATION D'UNE COMPOSITION PHARMACEUTIQUE DANS LE TRAITEMENT DE LA MIGRAINE
[Chinese]
药物组合物在治疗偏头痛上的应用
Applicants **
QI, Zhankai
Inventors
QI, Kevin
QI, Hyatt
Priority Data
202410977519.9
22.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1576 | |
| EPO | Filing, Examination, Granting | 8697 | |
| Japan | Filing, Examination, Granting | 2001 | |
| South Korea | Filing, Examination, Granting | 1805 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,819
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises cobra cardiotoxin (CDX) and a pharmaceutically acceptable carrier thereof. The pharmaceutical composition is further characterized by comprising use of cobra cardiotoxin (CDX) in combination with any one or both of the following drugs for treating migraine: cobra phospholipase A2 (PLA2) and cobra neurotoxin (NTX). The pharmaceutical composition can be used for preventing and treating migraine and down-regulating the concentration of nitric oxide (NO) in migraine patients. The pharmaceutical composition is of great significance for the treatment of migraine.[French]
La présente invention concerne une composition pharmaceutique. La composition pharmaceutique comprend une cardiotoxine cobra (CDX) et un support pharmaceutiquement acceptable de celle-ci. La composition pharmaceutique est en outre caractérisée en ce qu'elle comprend l'utilisation de cardiotoxine cobra (CDX) en combinaison avec l'un quelconque ou les deux médicaments suivants pour le traitement de la migraine : cobra phospholipase A2 (PLA2) et neurotoxine cobra (NTX). La composition pharmaceutique peut être utilisée pour prévenir et traiter la migraine et réguler à la baisse la concentration d'oxyde nitrique (NO) chez des patients migraineux. La composition pharmaceutique présente une grande importance pour le traitement de la migraine.[Chinese]
涉及一种药物组合，所述药物组合物包含眼镜蛇心脏毒素（CDX）和其药学上可接受的载体，所述药物组合物的特征还在于，它还包括眼镜蛇心脏毒素（CDX）和其他治疗偏头痛药物眼镜蛇磷脂酶A2（PLA2）、眼镜蛇神经毒素（NTX）中的任意一种或同时2种的联合使用。该药物组合物可以用来预防和治疗偏头痛，下调偏头痛患体内的一氧化氮（NO）的浓度，对偏头痛的治疗有着极其重要的意义。